Peptide Science Canberra

Peptide Science Canberra: Australia’s Capital of Biomolecular Innovation

Canberra, Australia’s national capital, has emerged as an unexpected but formidable hub for peptide science. While the city is best known for its political institutions and national monuments, it houses a concentration of world-class research infrastructure and scientific talent that has positioned it at the forefront of peptide and protein research. From the Australian National University’s Research School of Chemistry to the CSIRO’s agricultural biotechnology programs, Peptide Science Canberra community is driving innovations that span human health, agriculture, and industrial biotechnology.

The ARC Centre of Excellence for Innovations in Peptide and Protein Science

At the heart of Peptide Science Canberra ecosystem lies the Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS). This national centre represents a transformative $35 million investment from the Australian Government through the ARC Centres of Excellence scheme, supplemented by an additional $54 million in cash and in-kind contributions from national and international partners.

CIPPS brings together leading researchers from diverse disciplines to create a sustainable national research centre that drives new Australian industries and trains the next generation of researchers. The centre’s vision is ambitious: to discover nature’s untapped reservoir of peptides and proteins, decode their structures and functions, and develop enhanced synthetic technologies to address biology’s next grand challenge—the design of peptides and proteins for targeted scientific, agricultural, biotechnology, animal health and pharmaceutical applications.

The centre’s collaborative network spans major pharmaceutical companies including AstraZeneca and Novo Nordisk, agricultural biotechnology firms such as Innovate Ag, instrumentation leaders like AB Sciex and Vapourtec, manufacturing partners including Almac, and research organisations like CSIRO. This public-private partnership model ensures that fundamental research discoveries are translated into practical applications with tangible economic and social benefits.

The Australian National University: A Powerhouse of Peptide Research

The Australian National University’s Research School of Chemistry serves as the intellectual engine of Peptide Science Canberra community. Several research groups based at ANU are making significant contributions to the field, each with distinct areas of expertise.

The Malins Lab: Synthetic Tools for Peptide-Based Therapeutics

The Malins Lab, led by Associate Professor Lara Malins, operates at the interface of organic chemistry and chemical biology. The group focuses on developing versatile new synthetic tools for small molecule synthesis, protein bioconjugation, and the design of peptide-based therapeutics. By expanding the toolbox of practical methods and reagents for the direct modification of complex biomolecules, the Malins Lab seeks to understand the role of peptides in mediating biological processes and enhance their therapeutic potential.

Recent achievements from the Malins Lab include pioneering work on electrochemical peptide and protein modifications, which was published in the Journal of the American Chemical Society and selected as a Pick of the Week in Chemical Science. The group has also made significant contributions to umpolung peptide and protein modifications, providing new chemical strategies for creating previously inaccessible peptide structures.

The Nitsche Lab: Next-Generation Peptide Drug Candidates

Associate Professor Christoph Nitsche leads a dynamic, interdisciplinary research group at ANU that overcomes traditional boundaries between organic, inorganic and biological chemistry to develop next-generation peptide and protein drug candidates. The Nitsche Lab has received widespread recognition, being named a top medicinal chemistry lab for three consecutive years by Research Magazine, receiving the Rennie Memorial Medal for research excellence, and being named Lab of the Month by the American Peptide Society.

In 2025, Associate Professor Nitsche was awarded the Tregear Award for Outstanding Achievements in Peptide Science by the Australian Peptide Association, recognising his outstanding research in the field of peptide chemistry and biology. His research program focuses on medicinal chemistry and chemical biology, with particular emphasis on developing peptide therapeutics as next-generation antibiotics, antimalarials and anticancer agents.

One of the Nitsche Lab’s most notable achievements is the development of peptide–bismuth tricycles that demonstrate remarkable stability—fully withstanding cellular levels of glutathione, acting as nanomolar protease inhibitors without being proteolytically digested by their target, and remaining fully stable in human plasma. This innovative approach to peptide constraint represents a significant advance in the development of stable, bioavailable peptide therapeutics.

Dr Chloe Larcombe: Synthetic Methods for Peptide Modification

Dr Chloe Larcombe, who completed her PhD in the Malins Lab, now serves as an Evaluator at the Therapeutic Goods Administration in Canberra. Her research focused on developing new synthetic methods for the late-stage modification of peptides, with particular interest in solid-phase peptide synthesis linkers for C-terminal peptide modification. This expertise in peptide synthesis methodology is critical for the development of next-generation peptide therapeutics with enhanced stability and bioavailability.

CSIRO: Peptide Science for Agriculture and Food

The Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national science agency, maintains a significant presence in peptide research in Canberra. CSIRO’s contributions span multiple domains, from agricultural biotechnology to food science and biomedical manufacturing.

Professor Michelle Colgrave: Proteomics and Food Science

Professor Michelle Colgrave is Professor of Food and Agricultural Proteomics at CSIRO and holds a joint appointment at Edith Cowan University. She also serves as a Chief Investigator on the ARC Centre of Excellence for Innovations in Peptide and Protein Science. Colgrave uses proteomics—the study of proteins using mass spectrometry—to identify, characterise and quantify key proteins and peptides that benefit Australia’s food and agriculture industries and improve public health. She also leads CSIRO’s Future Protein initiative, positioning Australia at the forefront of alternative protein research.

Dr Andrew Kotze: Peptides for Parasite Control

Dr Andrew Kotze, an Associate Investigator with CIPPS at CSIRO Agriculture and Food, focuses on the control of insect and helminth parasites of livestock and humans. His research aims to discover new anthelmintic and insecticidal agents and characterise their molecular targets. Within the Centre, he explores the biological activities of discovered peptides as potential novel anthelmintic or insecticidal agents for the control of parasitic diseases. This work has significant implications for global food security and public health, particularly in developing regions where parasitic diseases remain a major burden.

Dr Paul Savage: Biomedical Manufacturing

Dr Paul Savage serves as Research Director of the Biomedical Manufacturing Platform at CSIRO and applies cutting-edge proteomics methodologies to characterise the structure, function, post-translational modifications and molecular properties of peptides and proteins. His work bridges fundamental peptide science and industrial application, helping to translate research discoveries into manufacturable products.

Machine Learning and Antimicrobial Peptides

CSIRO researchers in Canberra are also at the forefront of applying artificial intelligence to peptide discovery. Recent work has focused on developing machine learning-assisted prediction and generation of antimicrobial peptides—building predictive and generative algorithms that construct new peptide sequences, score their antimicrobial activity using machine learning models, identify amino acid motifs, and assemble high-ranking motifs into new peptide sequences. This computational approach dramatically accelerates the discovery of new antimicrobial peptides, which are urgently needed to combat the growing threat of antibiotic resistance.

Clinical and Commercial Applications

Canberra’s peptide science ecosystem extends beyond fundamental research into clinical and commercial applications. The city hosts a growing community of practitioners offering peptide therapies, with telehealth consultations provided by AHPRA-registered practitioners who assess whether peptide therapy may be appropriate. These therapies are dispensed through Australian compounding pharmacies, ensuring quality and safety.

The biotechnology sector in Canberra is also active in peptide-based therapeutics. EpiAxis Therapeutics, a Canberra-based company established in 2015 with investment from ANU Connect Ventures, is developing new treatments to minimise the recurrence of breast cancer. The company was the only Australian finalist in the Startup Slam, highlighting the commercial potential of peptide science emerging from Canberra’s research institutions.

The Australian Peptide Association

The Australian Peptide Association, formally established in 1983, plays a vital role in supporting and promoting research activities in peptide science across Australia. The association’s impact is remarkable: although Australians make up less than 1% of the world’s population, they produce 4% of its scientific output in peptide science. This outsized contribution reflects the quality and productivity of Australia’s peptide research community, with Canberra serving as one of its key centres.

The association organises regular conferences, including the Australian Peptide Conference and the International Peptide Symposium. The 13th International Peptide Symposium was held in conjunction with the 15th Australian Peptide Conference in Brisbane in October 2023, and the next Australian Peptide Conference is planned for around October 2025. These events provide critical forums for knowledge exchange and collaboration among peptide scientists from Australia and around the world.

Research Highlights and Emerging Directions

Canberra’s peptide scientists are pursuing research across the full spectrum of peptide science, from fundamental chemistry to applied therapeutics.

Cyclotides: Nature’s Knotted Peptides

Researchers in Canberra are studying cyclotides—unique macrocyclic peptides with interlocking loops, known as cyclic cystine knots. These peptides have shown potent medicinal properties for humans and an increased ability to bind to targets. Plants commonly produce cyclotides as defence agents to combat pests and pathogens. Understanding and harnessing these natural peptides could lead to new therapeutic agents and agricultural products.

Antimicrobial Peptides and Machine Learning

Canberra researchers have assembled a library of more than 600 antimicrobial peptides and are using machine learning for structure-function prediction. This iterative learning process involves using machine learning to reinvestigate genomes and transcriptomes to discover even more bioactives. This approach promises to dramatically expand the repertoire of antimicrobial peptides available for therapeutic development.

Bioinspired Peptide Stapling

Research in Canberra is also advancing bioinspired peptide stapling—chemical approaches to constrain peptides into stable, bioactive conformations. Stapling can enhance essential properties like selectivity, binding affinity, and bioavailability. These novel stapling approaches provide simple and effective means to create peptides with therapeutic potential.

Electrochemical Peptide Modifications

Canberra researchers are pioneering electrochemical approaches to peptide modification, offering more sustainable and selective methods for peptide synthesis. These techniques use 1,3-dithiane-based protecting groups for orthogonal protection of lysine ε-amines in peptide synthesis, avoiding the harsh conditions and excess reagents traditionally required.

Education and Outreach

The peptide science community in Canberra is deeply committed to nurturing the next generation of researchers. Outreach programs aim to enlighten high school science teachers and students in years 11 and 12 on peptide and protein science, inspiring inquisitive minds and scientific thinking. The Canberra Protein Group also runs seminar series featuring outstanding young biochemists, providing a platform for emerging researchers to present their work.

Future Prospects

Canberra’s position as a hub for peptide science is set to strengthen in the coming years. The substantial investment in CIPPS, combined with the expertise concentrated at ANU and CSIRO, provides a solid foundation for continued innovation. The integration of machine learning and artificial intelligence into peptide discovery, the development of novel synthetic methodologies, and the translation of fundamental research into clinical and commercial applications all point toward a vibrant future for peptide science in Australia’s capital.

The city’s peptide science community embodies the collaborative, interdisciplinary approach that modern scientific challenges demand. By bringing together chemists, biologists, clinicians, and industry partners, Canberra’s researchers are not only advancing fundamental knowledge but also creating practical solutions to some of the most pressing challenges in human health, food security, and environmental sustainability. As the field of peptide science continues to evolve, Canberra’s researchers will undoubtedly remain at the forefront, contributing to Australia’s outsized impact on this critical area of scientific endeavour.